GSK Rockville biologics manufacturing facility Acquired by Samsung Biologics | Manufacturing M&A Deal

Samsung Biologics has completed the acquisition of the GSK Rockville biologics manufacturing facility, a chemical manufacturing business in Maryland, for an undisclosed amount. Samsung Biologics acquires GSK Rockville biologics manufacturing facility to expand cGMP biologics production capacity in Rockville, supporting both clinical and commercial manufacturing. The Rockville site operates two cGMP plants with a combined 60,000-liter capacity and will continue producing products for GSK while Samsung Biologics scales contract manufacturing needs. Samsung Biologics acquisitions are structured as a divestiture acquisition, with more than 500 Rockville employees transitioning to the buyer as part of the manufacturing M&A. The strategic acquisition marks Samsung Biologics’ first U.S. manufacturing presence and includes planned capacity expansion and technology upgrades.